VJOncology is committed to improving our service to you

VJVirtual | MRx0518 + pembro in patients with resistance to therapy

VJOncology is committed to improving our service to you

Alex Stevenson

Alex Stevenson, PhD, 4D Pharma plc, Leeds, UK, talks about the latest updates in the clinical programme for MRx0518, a single strain live biotherapeutic in development for the treatment of cancer. Currently, the first part of the Phase I/II study has been successfully completed. The second part of the study has commenced and will evaluate the clinical benefit of MRx0518 in combination with pembrolizumab in patients with acquired resistance to prior immune checkpoint therapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter